Delaying BCG immunotherapy onset after transurethral resection of non-muscle-invasive bladder cancer is associated with adverse survival outcomes

PURPOSE: This study was carried out to assess whether a prolonged time between primary transurethral resection of non-muscle-invasive bladder cancer (TURB) and implementation of bacillus Calmette–Guerin (BCG) immunotherapy (time to BCG; TTBCG) is associated with adverse oncological survival in patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Krajewski, Wojciech, Moschini, Marco, Chorbińska, Joanna, Nowak, Łukasz, Poletajew, Sławomir, Tukiendorf, Andrzej, Afferi, Luca, Teoh, Jeremy Yuen-Chun, Muilwijk, Tim, Joniau, Steven, Tafuri, Alessandro, Antonelli, Alessandro, Cianflone, Francesco, Mari, Andrea, Di Trapani, Ettore, Hendricksen, Kees, Alvarez-Maestro, Mario, Rodríguez-Serrano, Andrea, Simone, Giuseppe, Zamboni, Stefania, Simeone, Claudio, Marconi, Maria Cristina, Mastroianni, Riccardo, Ploussard, Guillaume, Laukhtina, Ekaterina, Tully, Karl, Kołodziej, Anna, Krajewska, Joanna, Piszczek, Radosław, Xylinas, Evanguelos, Zdrojowy, Romuald
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8332577/
https://www.ncbi.nlm.nih.gov/pubmed/33230571
http://dx.doi.org/10.1007/s00345-020-03522-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8332577/
https://www.ncbi.nlm.nih.gov/pubmed/33230571
http://dx.doi.org/10.1007/s00345-020-03522-3

Ejemplares similares